Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
KT-621 · 4 trials · 3 indications
| Arm | Type | Description |
|---|---|---|
| KT-621 | EXPERIMENTAL | - |
| Group 1: KT-621 Dose 1 | EXPERIMENTAL | - |
| Group 2: KT-621 Dose 2 | EXPERIMENTAL | - |
| Group 3: KT-621 Dose 3 | EXPERIMENTAL | - |
| Group 4: Placebo | PLACEBO_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| KT-621 | DRUG | Oral drug |
| Placebo | OTHER | Oral placebo matched to KT-621 |
Inclusion Criteria: * Must have completed all visits of the parent study, per its protocol, up to the end of treatment (EoT) visit. * Must be willing and able to comply with scheduled visits, treatment plan, laboratory tests, other study-related procedures, and questionnaires, including completing ...
KT-621 is an oral small molecule drug developed by Kymera Therapeutics, Inc. (ticker KYMR) that targets STAT6. It is being studied in Phase 2 clinical trials for asthma, including eosinophilic asthma, and for atopic dermatitis. KT-621 has received FDA Fast Track designation.
KT-621 is being developed to treat respiratory and inflammatory conditions, specifically asthma (diagnosis), eosinophilic asthma, and atopic dermatitis. It is an investigational therapy and has not been approved for any indication. Clinical studies are enrolling adults with asthma and adults and adolescents with atopic dermatitis.
KT-621 targets STAT6, a protein involved in inflammatory signaling. By binding STAT6, the oral small molecule is designed to modulate the pathway that drives type 2 inflammation associated with conditions such as asthma and atopic dermatitis. STAT6 is the molecular target of KT-621.
KT-621 is developed by Kymera Therapeutics, Inc., which trades under the ticker KYMR. Kymera is the sponsor of the clinical trials evaluating KT-621 in asthma and atopic dermatitis.
KT-621 is in Phase 2 clinical development. It is investigational and has not been approved by the FDA. The Phase 2 program includes studies in asthma and atopic dermatitis, and KT-621 has been granted FDA Fast Track designation.
KT-621 is being evaluated in several trials. NCT07677059 is a Phase 2 long-term study in asthma. NCT07323654 is a Phase 2 study in moderate to severe eosinophilic asthma. NCT07217015 is a Phase 2 study in moderate to severe atopic dermatitis. NCT06945458 was a completed Phase 1 study in atopic dermatitis.